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To evaluate whether androgen deprivation impacts late rectal toxicity in patients with localised prostate carcinoma treated
with three-dimensional conformal radiotherapy. One hundred and eighty-two consecutive patients treated with 3DCRT
between 1995 and 1999 at our Institution and with at least 12 months follow-up were analysed. three-dimensional conformal
radiotherapy consisted in 70–76 Gy delivered with a conformal 3-ﬁeld arrangement to the prostate+seminal vesicles. As part
of treatment, 117 patients (64%) received neo-adjuvant and concomitant androgen deprivation while 88 (48.4%) patients
were continued on androgen deprivation at the end of three-dimensional conformal radiotherapy as well. Late rectal toxicity
was graded according to the RTOG morbidity scoring scale. Median follow up is 25.8 (range: 12–70.2 months). The 2-year
actuarial likelihood of grade 2–4 rectal toxicity was 21.8+3.2%. A multivariate analysis identiﬁed the use of adjuvant androgen
deprivation (P=0.0196) along with the dose to the posterior wall of the rectum on the central axis (P=0.0055) and the grade
of acute rectal toxicity (P=0.0172) as independent predictors of grade 2–4 late rectal toxicity. The 2-year estimates of grade
2–4 late rectal toxicity for patients receiving or not adjuvant hormonal treatment were 30.3+5.2% and 14.1+3.8%,
respectively. Rectal tolerance is reduced in presence of adjuvant androgen deprivation.
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Several trials have shown some advantage of adding androgen
deprivation (AD) to conventional radiotherapy to 66–70 Gy for
prostate carcinoma (Bolla et al, 1997; Lawton et al, 2001; Zagars
et al, 1988; Granfors et al, 1998) although improved overall survival
was observed only in one (Bolla et al, 1997).
On the other hand, a prospective trial suggests that, when loca-
lised prostate cancer is treated by radiotherapy alone, dose
escalation to the total dose of 78 Gy with three-dimensional
conformal radiotherapy (3DCRT) leads to improved outcome over
70 Gy (Pollack et al, 2000). However, despite ameliorations in
radiotherapy treatment planning and delivery, late toxicity on both
bladder and rectum remains a limiting factor in dose escalation for
prostate carcinoma due to the proximity of these organs to the
target.
The next logical step would be the combination of the two
modalities, radiotherapy dose escalation and adjuvant AD (AAD),
as it is currently being investigated by the European Organisation
for Reseach and Treatment of Cancer within two separate phase
III studies (22991 and 22961). However, whether the addition of
AAD to high-dose 3DCRT reduces rectal tolerance and, therefore,
whether radiotherapy dose escalation is feasible in presence of
AAD is essentially an unaddressed issue.
While some quoted studies did not even mention late toxi-
city (Pollack et al, 1995; Zagars et al, 1999; Laverdiere et al,
1997), some other reports may suggest a reduced tolerance of
both genitourinary and gastrointestinal systems in presence of
AAD (Bolla et al, 1997; Fiorino et al, 2001; Sanguineti et al,
2000).
In a previous analysis we had found that AAD was associated
with an increased risk of late rectal toxicity (Sanguineti et al,
2000). However, in that analysis, due to a large time-span, an
heterogeneous population of patients with localised prostate cancer
was considered. Moreover, treatment related parameters, that can
be inﬂuenced by AD, were not taken into account. Thus, in the
present paper we focused on a homogeneously treated patients
for whom technical details of treatment were prospectively
recorded.
MATERIALS AND METHODS
Patient population
We analysed 188 consecutive patients with prostate cancer, trea-
ted at our institution with 3DCRT on the prostate+seminal
vesicles from 1995 to 1999. Of all patients referred to us during
this time period for radical treatment, we only excluded six
patients without 12 months minimum follow-up, because of
early death due to intercurrent causes (4 patients) or distant
metastases (2 patients) thus leaving 182 patients for analysis.
According to the 1997 UICC staging system, six (3.2%) patients
were classiﬁed as T1b, 40 (22%) as T1c, 66 as T2a (36.3%), 26
(14.3%) as T2b, 30 as T3a (16.5%) and 14 (7.7%) as T3b. The
median age was 71.5 years ranging from 50–83 years. No patient
had evidence of pelvic lymph node involvement at diagnosis
(N0–Nx).
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Our prescription dose for T51b prostate cancer has changed
during years. From 1995 to 1998, only patients with T52a prostate
carcinoma were prescribed 76 Gy, with 70 Gy to T1 stages. From
1999 all patients with primary tumour staged 51b were adminis-
tered 76 Gy. The only exception to higher dose RT was represented
by patients with diabetes mellitus and severe cardiovascular disease,
who were always prescribed 70 Gy.
Regarding target volumes, treatment was limited to the prosta-
te+seminal vesicles (SV). For SV inclusion we followed the
guidelines reported by Katcher et al (1997). The whole pelvis was
never treated.
In our experience, neoadjuvant hormonal therapy prescription
was related mainly to the referring urologist rather than the volume
of prostate gland at diagnosis (Zelefsky and Harrison, 1997). Patients
undergoing neoadjuvant AD were typically prescribed monthly or
trimonthly LH–RH analogue preceded by 2–3 weeks of anti-andro-
gens. In fact, we collect patients from three different urology
departments and several private practices; they refer us patients after
neoadjuvant AD has been already started. This along with the fact
that data about the efﬁcacy of neoadjuvant AD changed during years
(Pilepich et al, 1995; Laverdiere et al, 1997), resulted in a wide spec-
trum of indications and duration of neoadjuvant AD. As result, all
but 65 patients (117 patients, 64%) underwent neoadjuvant AD for
a median duration of 4.2 months (0.4–67.2 months) before 3DCRT.
Our policy was to leave hormonal treatment during radiother-
apy for those patients who had already started it. Eighty-eight
(48.4%) patients with Gleason score greater than 6 or PSA at diag-
nosis greater than 20 ng ml
71 were continued on adjuvant AD for
a minimum of 1 year after treatment end.
Treatment technique
On average simulation was performed 2.1 weeks (range: 0.1–7
wks) before 3DCRT.
X-ray simulation was performed before planning CT scanning in
order to deﬁne the position of the isocenter and to obtain two
orthogonal (0 and 90 degrees) 10610 cm ﬁlms for reference
purposes. Patients were immobilised supine in a thermoplastic
device with empty rectum and bladder. The preliminary position
of the isocenter was marked on the mask. Isocenter was typically
positioned at mid pubic symphysis level on the midline on AP
ﬁelds, and behind the femoral heads on lateral ﬁelds. A fenestration
was cut in the device at the level of the transverse lasers and the
patient skin was tattooed accordingly on both sides in order to
better align the patient to the mask.
CT was performed with a dedicated scanner and slices were
taken at 5 mm intervals covering the whole target. The clinical
target volume (prostate+seminal vesicles)(CTV), the rectum
(outer contour) and the bladder were drawn on CT slices. Until
July 1997, only 6–10 representative CT slices were loaded in the
treatment planning system (Nucletron Plato); afterwards all slices
(20–25) were included.
The planning target volume (PTV) was obtained by adding
1.3 cm to CTV except at the prostate–rectum interface where a
0.8-cm margin was used. An additional 0.5-cm margin was added
circumferentially around the PTV to account for radiation beam
penumbra. A 1-cm multileaf collimator was used to shape the
ﬁelds according to beam’s eye view ﬁndings. Our 3D conformal
radiotherapy set-up involves three isocentric coplanar photon (15
MV) ﬁelds (0, 110 and 250 degrees) (Figure 1).
The radiation dose was prescribed to the isocenter (International
Commission on Radiation Units and Measurements point). When
initially included in target (‘initial phase’), the seminal vesicles were
excluded at 60 Gy (‘boost phase’). A dose distribution was
obtained at central axis level in order to optimize beam weights.
No wedges were used.
Statistics
Patients were seen 3 months after treatment end and every 6
months afterwards. Rectal complications were scored according
to Radiation Therapy Oncology Group scale (Cox et al, 1995).
Acute ones were deﬁned as those occurring during treatment or
within 90 days from its completion. Late complications were those
developing more than 90 days after treatment end or those starting
prior to and persisting for longer than 90 days after completion of
treatment (Table 1).
Survival curves were calculated using the Kaplan–Meier method
from the date of treatment end. Actuarial incidence of grade 2–4
reactions was analysed in relation to clinical, anatomical and dosi-
metric/geometric variables using univariate and multivariate
analyses. Clinical variables were: age (on a continuum), diabetes
mellitus (no vs yes), vascular comorbidity (according to Kaplan–
Feinstein (Piccirillo and Feinstein, 1996)) (grades 0–1 vs 2–3),
T stage (T1 vs T2 vs T3) and acute rectal toxicity (grades 0–1 vs
2–3).
On the central slice, where the isocenter was located, the follow-
ing parameters were identiﬁed (Figure 1): rectal wall thickness (AB
distance on a continuum); depth of oblique ﬁelds (distance between
the posterior edge of oblique ﬁelds and the anterior margin of the
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Figure 1 Geometrical parameters at central axis level. (A) anterior rec-
tal dose; (B) posterior rectal dose; (C) depth of oblique ﬁelds; dashed lines:
open ﬁeld borders; solid lines: posterior edge of lateral ﬁelds as from MLC.
Table 1 Late rectal toxicity score
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
None Slight rectal discharge
or bleeding
Excessive rectal mucus
or intermittent bleeding
Obstruction or bleeding
requiring surgery
Necrosis, perforation,
ﬁstula
Death
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normalised to rectum thickness (ratio between AC and AB on a
continuum); posterior rectal wall dose (at point B on a conti-
nuum), anterior rectal wall dose (at point A on a continuum).
Other included factors were: radiation oncologist (GU dedicated
vs occasional), neoadjuvant+concomitant AD (no vs yes), adjuvant
AD (no vs yes), duration of radiotherapy (on a continuum), inter-
val time between simulation and radiotherapy (on a continuum),
target volumes (prostate vs prostate+SV), ICRU prescribed dose
(70 Gy vs 76 Gy), number of slices of CT loaded in the treatment
planning system (410 vs 410).
Moreover, for both the initial and boost phases we considered
the height of ﬁelds and the volume of irradiated volume (on a
continuum). This was assumed to be a box whose volume is the
average of the ones calculated for each ﬁeld (cubic root of the
product of the volume of each ﬁeld). Each irradiated volume was
obtained by multiplying the effective area of the corresponding
ﬁeld and a depth. The former was provided by computerised analy-
sis of the multileaf ﬁle. The latter is calculated by the square root of
the effective area as follows. The square root of the AP ﬁeld
provides an estimate of the depth of the laterals; the depth of
the AP ﬁeld is the average of the square root of each lateral ﬁeld.
For patients treated on the prostate alone, the initial and the
boost phase were considered to be the same.
Univariate analysis was performed with the log-rank test and
multivariate analysis was performed using the Cox proportional
hazards model with both forward and backward stepwise proce-
dures. Variables with a P40.2 at univariate analysis were entered
in the multivariate one. Unless otherwise speciﬁed, median values
have been chosen as cut-off values. In all cases, statistical signiﬁ-
cance was claimed for P50.05. Median follow-up is 25.8 months
(range: 12–70.2 months).
RESULTS
Thirty-four (18.7%), one (0.5%) and one (0.5%) patients devel-
oped grade 2, 3 or 4 late rectal toxicity, respectively. Median
time to onset of late toxicity was 10.1 months (range: 3–22.6
months). The estimated incidence of grade 2–4 late reactions is
21.8+3.2% at 2 years (Figure 2).
Univariate analysis data are shown in Table 2. T stage (P50.01),
adjuvant hormonal therapy (P=0.01), irradiated volume of the
initial phase (P=0.04), depth of oblique ﬁelds of initial phase by
rectal width (P50.01), acute rectal toxicity (P50.01), posterior
and anterior doses to the rectum on the central axis (P50.01
and 0.03, respectively) were signiﬁcant. A trend was found for
height of PTV during the initial phase (P=0.09), depth of oblique
ﬁelds of initial phase (P=0.07), depth of oblique ﬁelds of boost
phase by rectal width (P=0.09) and prescribed volumes (P=0.09).
At multivariate analysis (Table 3), the posterior dose to the
rectum, adjuvant hormonal therapy and acute rectal toxicity were
independent predictors of late rectal toxicity. No other variable
was signiﬁcant. In particular anterior dose was not signiﬁcant as
either continuous or categorised variable.
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Figure 2 Actuarial incidence (+s.e.) of grade 2–4 late rectal toxicity in
the whole group of patients.
Table 2 Late rectal toxicity: univariate analysis. Only variables showing a P value equal or less
than 0.2 are reported
Parameter Stratiﬁcation Points HR (95% CI) P value
T stage T1 46 1 50.01
T2 92 1.61 (0.59–4.45)
T3 44 4.04 (1.48–11.1)
Treating physician GU dedicated 162 1 0.19
Occasional 20 1.78 (0.74–4.29)
Adjuvant AD No 94 1 0.01
Yes 88 2.37 (1.18–4.75)
Acute rectal toxicity Grade 0–1 146 1 50.01
Grade 2–3 36 2.54 (1.28–5.02)
Irradiated volume I Continuum 182 1.00 (0.99–1.00) 0.04
Irradiated volume II Continuum 182 1.00 (1.00–1.00) 0.20
Height of PTV I Continuum 182 1.13 (0.98–1.30) 0.09
Depth of oblique ﬁelds I Continuum 182 1.31 (0.97–1.77) 0.07
Depth of oblique ﬁelds I by rectal width Continuum 182 3.06 (1.37–6.80) 50.01
Depth of oblique ﬁelds II by rectal width Continuum 182 2.45 (0.86–6.95) 0.09
Volumes Prostate only 41 1 0.09
Prostate+SV 141 1.85 (0.91–3.79)
Posterior dose to the rectum Continuum 182 1.04 (1.01–1.07) 50.01
Anterior dose to the rectum Continuum 182 1.12 (1.01–1.24) 0.03
Abbreviations: AD=androgen deprivation; PTV=planning target volume; I=initial phase (prostate+seminal
vesicles); II=boost phase (prostate only).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1843–1847Patients receiving adjuvant hormones have a risk of grade 2–4
rectal toxicity which is 2.23 times greater (95% CI: 1.11–4.50,
P=0.0196) than that of patients not receiving hormones. The 2-year
estimate of grade 2–4 late rectal toxicity for patients receiving or
not adjuvant hormonal treatment were 30.3+5.2% and
14.1+3.8%, respectively (Figure 3).
DISCUSSION
Radiation induced late rectal toxicity has been taken as surrogate
for dose escalation feasibility of 3DCRT for prostate carcinoma.
Contrary to toxicity to the bladder, that is the other organ limiting
dose escalation, rectal toxicity usually develops sooner (Mameghan
et al, 1990) and it has also been shown to be correlated to physical
parameters of treatment such as dose and volume (Fiorino et al,
2001; Boersma et al, 1998). There are, however, important draw-
backs. Severe (grade 3 or more) late complications (Table 1)
develop in a minority (51–2%) of patients (Dearnaley et al,
1999; Storey et al, 2000; Skwarchuk et al, 2000; Schultheiss et al,
1995). Their rarity makes late toxicity analysis not comparable with-
in small, prospective, single-institution trials. On the other hand, a
reliable estimate of grade 2 late rectal toxicity is hampered by
several pitfalls. While severe or higher late complications are unli-
kely to escape documentation and are easily recognised according
to the RTOG scale (Table 1), the scoring of less severe complica-
tions might be subjective, thus questioning its reproducibility
within multicenter trials. This fact also justiﬁes the introduction
of modiﬁcations in the RTOG scale (Hanlon et al, 1997).
The knowledge of individual radiotherapy treatment data is also
crucial to analysis. Neoadjuvant hormonal therapy is known to
induce modiﬁcations of prostate gland volume (Zelefsky and Harri-
son, 1997; Forman et al, 1995; Marcenaro et al, 2001). Patients
undergoing 3-month neoadjuvant AD may have a reduced risk of
late toxicity throughout a more favourable geometry of the treat-
ment of a shrunk prostate gland (Zelefsky and Harrison, 1997).
On the other hand, if such shrinkage is not taken into account at
radiotherapy treatment planning, an increased risk of complications
is also possible (Marcenaro et al, 2001; Schultheiss et al, 1995).
All these biases may have affected previous reports on late rectal
toxicity to some extent (Bolla et al, 1997; Sanguineti et al, 2000;
Lawton et al, 2001). Contrary to our previous analysis, we tried
to minimise the impact of such biases by considering a homoge-
neously treated group of patients for whom treatment details
were available. Moreover, late reactions were prospectively recorded
at a single institution by just two observers (G Sanguineti and P
Franzone). Similarly to other authors (Haie-Meder et al, 1994)
we scored also moderate, grade 2, reactions.
Our results show that rectal tolerance is reduced in presence of
adjuvant hormonal therapy. The same conclusion comes also from
the study of Fiorino et al (2001), where, similarly to our experi-
ence, individual dose/volume histograms (DVH) of the rectum
were kept in the analysis. In the experience of Fiorino et al
(2001), AAD along with ICRU total dose and DVHs of the rectum
were independent predictors of grade 2+ late rectal bleeding. In
particular, patients undergoing AAD had a 2.8 (95% CI: 1.0–
7.9) increased risk of grade 2+ late rectal bleeding, which is close
to our estimate (Table 3).
The underlying mechanism of such phenomenon is not known.
After radiotherapy, chronic pathologic changes occurring in the
rectum include ﬁbrosis and vascular insufﬁciency (Coia et al,
1995). Main changes involve the submucosa where atypical ﬁbro-
blasts, collagen proliferation, thickening of walls of small arteries
and telangiectatic vessels can be found. The fact that neoadjuvant
AD has little impact on late rectal toxicity compared to adjuvant
AD suggests that androgen deprivation may hamper the reparative
process of the rectal tissue that is damaged by radiotherapy.
Further studies are needed to elucidate this and other aspects such
as the duration of AAD and the type of hormonal therapy.
The clinical impact of our ﬁndings might be somewhat limited
since most of our toxicities were moderate ones (grade 2)
althought even less intense late rectal reactions can bother patients
quality of life and quality of function (Lilleby et al, 1999).
Moreover, since even with conformal radiotherapy, the prescribed
total dose to the target is close to the tolerance of neighbouring
organs such as rectum and bladder, our ﬁndings should be carefully
taken into account when combining high-dose 3DCRT and AAD.
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